Humanigen to Host Investor Conference Call to Discuss NIH's Selection of Lenzilumab for Big …

… antibody drug candidate, as an agent to be evaluated in the NIAID-sponsored Big Effect Trial (BET) in hospitalized patients with COVID-19.